Catalent Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
16,900
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
29
- Investments
-
33
Catalent General Information
Description
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
Contact Information
Website
www.catalent.comCorporate Office
- 14 Schoolhouse Road
- NJ 08873
- United States
Corporate Office
- 14 Schoolhouse Road
- NJ 08873
- United States
Catalent Timeline
Catalent Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Catalent Comparisons
Industry
Financing
Details
Catalent Competitors (37)
One of Catalent’s 37 competitors is Recipharm, a Private Equity-Backed company based in Stockholm, Sweden.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Recipharm | Private Equity-Backed | Stockholm, Sweden | ||||
| Pharmaceutics International | Formerly PE-Backed | Hunt Valley, MD | ||||
| Alcami | Private Equity-Backed | Wilmington, NC | ||||
| Pnp Pharmaceuticals | Private Equity-Backed | Burnaby, Canada | ||||
| CoreRx | Private Equity-Backed | Clearwater, FL |
Catalent Patents
Catalent Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240342673-A1 | Systems and methods for providing optimal process parameters for fluid bed granulation systems | Pending | 14-Apr-2023 | ||
| US-20250108012-A1 | Softgel capsules and a method for preparing the softgel capsules | Pending | 14-Dec-2022 | ||
| US-20240165041-A1 | Softgel capsule and method of marking a softgel capsule | Pending | 23-Nov-2022 | ||
| US-20240164990-A1 | Softgel capsule and method of marking a softgel capsule | Pending | 23-Nov-2022 | ||
| AU-2023342872-A1 | Method of differentiation of pluripotent stem cells to hematopoietic precursor and stem cells | Pending | 13-Sep-2022 | C12N5/0646 |
Catalent Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Catalent Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Catalent Investments & Acquisitions (33)
Catalent’s most recent deal was a Merger/Acquisition with Metrics Contract Services for . The deal was made on 04-Oct-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Metrics Contract Services | 04-Oct-2022 | Merger/Acquisition | Discovery Tools (Healthcare) | ||
| Erytech Pharma (30,900 sq.ft. Commercial Scale Cell Therapy Manufacturing Facility in Princeton, NJ) | 12-Apr-2022 | Corporate Asset Purchase | Buildings and Property | ||
| VMIC (Biologics Development and Manufacturing Facility in Oxford, United Kingdom) | 05-Apr-2022 | Corporate Asset Purchase | Buildings and Property | ||
| Bettera Wellness | 01-Oct-2021 | Merger/Acquisition | BPO/Outsource Services | ||
| Rheincell Therapeutics | 04-Aug-2021 | Merger/Acquisition | Biotechnology |
Catalent Exits (3)
Catalent’s most recent exit was on 28-Jun-2018 from PhenomeX. The exit was categorized as with 10 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| PhenomeX | 28-Jun-2018 | Completed |
|
||
| Lexent Bio | 01-Nov-2017 | Completed |
|
||
| Osny Pharma | Merger/Acquisition | Completed |
Catalent Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Redwood Bioscience | Emeryville, CA | 2008 | |
| Pts Intermediate Holdings | Somerset, NJ | 2007 |
Catalent FAQs
-
When was Catalent founded?
Catalent was founded in 2007.
-
Where is Catalent headquartered?
Catalent is headquartered in NJ.
-
What is the size of Catalent?
Catalent has 16,900 total employees.
-
What industry is Catalent in?
Catalent’s primary industry is BPO/Outsource Services.
-
Is Catalent a private or public company?
Catalent is a Private company.
-
What is the current valuation of Catalent?
The current valuation of Catalent is .
-
What is Catalent’s current revenue?
The current revenue for Catalent is .
-
How much funding has Catalent raised over time?
Catalent has raised $9.6B.
-
Who are Catalent’s investors?
Novo Holdings has invested in Catalent.
-
Who are Catalent’s competitors?
Recipharm, Pharmaceutics International, Alcami, Pnp Pharmaceuticals, and CoreRx are some of the 37 competitors of Catalent.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
